AZD6234
AZD6234, long-acting amylin analog
AstraZeneca's weekly amylin analog that jumped to Phase 3 in 2026 as a monotherapy and as an add-on to GLP-1 drugs, with detailed Phase 2 numbers still unpublished.
Overview
AZD6234 is a once-weekly amylin receptor agonist. AstraZeneca registered several Phase 3 trials in 2026 covering obesity with and without type 2 diabetes, including a study adding it to an incretin drug. Public efficacy data are limited, so its entry here reflects development stage rather than proven effect.
Mechanism of action
Long-acting amylin receptor agonism that promotes satiety and slows gastric emptying.
Key studies & citations
- Human2026
AZD6234 Phase 3 in adults with obesity
Pivotal trial registered without published Phase 2 efficacy detail.
ClinicalTrials.gov NCT07784725 - Human2025
AZD6234 as add-on to incretin therapy (Phase 2)
Tests the amylin plus GLP-1 combination.
ClinicalTrials.gov NCT06851858
Frequently asked questions
Why are so many companies building amylin drugs?
Amylin adds weight loss through a non-GLP-1 pathway with different side effects, which makes it attractive both alone and layered on incretin drugs.